Xigduo XR Shortage: What Providers and Prescribers Need to Know in 2026

Prescribers managing patients on Xigduo XR (dapagliflozin/metformin HCl extended-release) are encountering a complex access landscape in 2026. While no official FDA shortage has been declared, patients are experiencing meaningful difficulty finding the medication at pharmacies — and the reasons are multifactorial. This clinical guide provides prescribers with a clear picture of what's happening and actionable strategies for managing affected patients.

Current Availability Status

As of 2026, Xigduo XR is not on the FDA's Official Drug Shortage List. However, availability is inconsistent at the pharmacy level due to:

Brand-to-generic transition: Generic dapagliflozin/metformin ER (FDA-approved early 2026 from Aurobindo and Lupin) is still ramping up distribution. Many pharmacies have reduced brand inventory while generics are not yet uniformly available.

Insurance formulary restrictions: Most Medicare Part D plans and many commercial plans do not cover brand Xigduo XR without prior authorization. Step therapy requirements — often mandating a trial of Synjardy first — are common.

Localized pharmacy stocking decisions: Pharmacies make inventory decisions based on local prescription volume. Low-volume pharmacies may not routinely stock all five strength combinations of Xigduo XR.

Increased overall demand for dapagliflozin: Expanded FDA approvals (heart failure 2020, CKD 2021) have significantly increased prescribing across specialties.

Therapeutic Alternatives: A Clinical Overview

When Xigduo XR is unavailable or not covered, clinicians have several evidence-based alternatives to consider. The choice should be guided by the patient's primary indication, cardiovascular and renal risk profile, insurance formulary, and cost.

Option A: Prescribe Dapagliflozin and Metformin XR Separately

The most pharmacologically equivalent option is to prescribe the two components — dapagliflozin (Farxiga or generic) and metformin XR (generic) — as separate prescriptions. Generic metformin XR is widely stocked at essentially every pharmacy. Generic dapagliflozin became available in 2025 and is increasingly accessible.

This approach maintains the same therapeutic effect, preserves all dapagliflozin's FDA-approved indications, and is often covered more favorably by insurance. The only practical downside is two pills instead of one.

Option B: Synjardy XR (Empagliflozin/Metformin ER)

Synjardy XR is the most commonly preferred formulary alternative among insurance plans. From a clinical standpoint, empagliflozin and dapagliflozin are both SGLT2 inhibitors with proven cardiovascular and renal outcome data, though their trial populations and specific indications differ slightly.

Clinical considerations when switching:

EMPA-REG OUTCOME (empagliflozin) demonstrated reduced cardiovascular mortality in T2DM + established ASCVD

DAPA-HF (dapagliflozin) demonstrated HF benefit in both HFrEF with and without T2DM — a unique indication not shared by empagliflozin Synjardy XR

DAPA-CKD (dapagliflozin) showed benefit in non-diabetic CKD — consider whether switching would maintain this indication

Synjardy XR is often the step-1 preferred agent for SGLT2/metformin combinations on commercial and UHC formularies

Option C: Invokamet XR (Canagliflozin/Metformin ER)

Invokamet XR is pharmacologically similar but carries a boxed warning for increased risk of lower limb amputation. Before prescribing, confirm the patient has no history of peripheral arterial disease, prior amputation, or active foot ulcer. For appropriate patients, it offers equivalent glycemic control and cardiovascular risk reduction in T2DM + established ASCVD (CANVAS trial).

Prescribing Tips for Better Access

To help your patients avoid access issues with Xigduo XR or its alternatives, consider these prescribing practices:

Write DAW=0 (dispense as written = no): Allow generic substitution so pharmacies can automatically dispense generic dapagliflozin/metformin ER if brand is unavailable.

Consider separate-component prescribing: Dapagliflozin + metformin XR separately is pharmacologically equivalent and often more accessible.

Check the patient's formulary first: Before prescribing brand Xigduo XR, check whether the patient's plan requires prior authorization or step therapy. Submit the PA proactively.

Document medical necessity: If brand Xigduo XR is medically necessary (e.g., patient cannot tolerate the alternative formulation), document this in the chart to support the PA.

Prescribe 90-day supplies: For stable patients, 90-day fills via mail order reduce access disruptions.

Counseling Patients on Access Challenges

When a patient reports difficulty filling Xigduo XR, advise them to:

Ask specifically for generic dapagliflozin/metformin ER, not just "Xigduo XR"

Try independent pharmacies, which may have different wholesaler access

Use medfinder, a service that calls pharmacies to check which ones have the medication in stock, texting the patient the results

Do not abruptly stop the medication — contact your office for a bridge prescription if needed

Outlook

The availability landscape for Xigduo XR and generic dapagliflozin/metformin ER is improving as multiple generic manufacturers ramp up production and formulary coverage for generics expands. Prescribers can expect the brand-to-generic transition to ease access substantially over the course of 2026. In the meantime, proactive prescribing strategies and early communication with patients about access options will minimize treatment disruptions.

See also our detailed guide: How to help your patients find Xigduo XR in stock.